November 25, 2022
1 minute read
The American Gastroenterological Association recently updated its guidelines for refractory celiac disease, with a step-by-step approach to following a gluten-free diet and information about tests and treatments.
Among its recommendations, the American Gastroenterological Association (AGA) said that corticosteroids such as open-capsule budesonide or prednisone should be used as first-line therapy in type 1 or type 2 refractory celiac disease. It was the top story in gastroenterology last week.
Other top stories were based on presentations from the American College of Gastroenterology (ACG) Annual Scientific Meeting. In one presentation, researchers reported that a vibrating capsule was safe and well tolerated in patients with chronic idiopathic constipation.
Read these and more top gastroenterology stories below:
AGA publishes 10 best practice statements for the treatment of refractory celiac disease
In an expert review published in gastroenterology, AGA has provided updated guidelines for the diagnosis and management of refractory celiac disease, including supportive and therapeutic treatment options and monitoring recommendations. Read more.
Vibrating capsule safe, well yes–tolerated, easy to use in chronic idiopathic constipation
An orally ingested vibrating capsule was found to be safe, well tolerated and easy to use for the treatment of chronic idiopathic constipation, according to data presented at ACG’s annual scientific meeting. Read more.
Follow-up surveillance within 5 years can detect CRC after colonoscopy
The recommended surveillance interval was the most important modifiable risk factor for post-colonoscopy colorectal cancer at 3 years, data show. Read more.
IBD specialists, not physicians, have a greater EHR burden in gastroenterology
In gastroenterology practices, inflammatory bowel disease specialists and non-doctors experienced an increased burden on electronic health records, according to a presenter at ACG’s annual scientific meeting. Read more.
Holding IBD therapy for COVID-19 vaccine ‘has no impact’ on infection, risk of hospitalization
Withholding immunosuppressive therapy prior to or after COVID-19 vaccination did not affect the rate of breakthrough infections or hospitalizations in patients with inflammatory bowel disease, one presenter noted. Read more.